https://www.selleckchem.com/pr....oducts/chitosan-olig
123; 95% CI 0.730-1.728, P=0.596) or MACE (HR, 1.107; 95% CI 0.463-2.648, P=0.819) in patients with DOAC only, whereas in patients with add-on antiplatelets, off-label dose reduction significantly reduced bleeding (HR, 0.429; 95% CI 0.212-0.868, P=0.019) without increasing MACE (HR, 2.205; 95% CI 0.424-11.477, P=0.348). Conclusions Reduced DOAC dose in combination with antiplatelet agents was associated with fewer bleeding complications than standard-dose therapy with no reduction in efficacy.Background Studies comparin
Like
Comment
Share
